{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:11:02Z","timestamp":1794006662860,"version":"4.8.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470416"],"award-info":[{"award-number":["82470416"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022963","name":"Key Research and Development Program of Zhejiang Province","doi-asserted-by":"publisher","award":["2025C02054"],"award-info":[{"award-number":["2025C02054"]}],"id":[{"id":"10.13039\/100022963","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.critrevonc.2026.105227","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:18:53Z","timestamp":1772036333000},"page":"105227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Navigating the complex landscape of duodenal gastrointestinal stromal tumor: Innovations in diagnosis and treatment"],"prefix":"10.1016","volume":"221","author":[{"given":"Weixun","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bixian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihua","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.critrevonc.2026.105227_bib1","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1158\/1078-0432.CCR-17-3795","article-title":"Preclinical antitumor activity of a novel anti-c-KIT antibody-drug conjugate against mutant and wild-type c-KIT-positive solid tumors","volume":"24","author":"Abrams","year":"2018","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"72","key":"10.1016\/j.critrevonc.2026.105227_bib2","first-page":"357","article-title":"Gastrointestinal stromal tumors (GIST): A rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes","volume":"13","author":"Blay","year":"2012","journal-title":"Discov. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105227_bib3","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105227_bib4","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.3390\/molecules22122152","article-title":"A novel receptor tyrosine kinase switch promotes gastrointestinal stromal tumor drug resistance","volume":"22","author":"Boichuk","year":"2017","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105227_bib5","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamaoncol.2016.0256","article-title":"Molecular subtypes of KIT\/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health gastrointestinal stromal tumor clinic","volume":"2","author":"Boikos","year":"2016","journal-title":"JAMA Oncol."},{"issue":"22","key":"10.1016\/j.critrevonc.2026.105227_bib6","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.3748\/wjg.v16.i22.2788","article-title":"Segmental duodenectomy for gastrointestinal stromal tumor of the duodenum","volume":"16","author":"Buchs","year":"2010","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105227_bib7","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s11523-021-00820-7","article-title":"Starting imatinib at 400 mg daily in patients with gastrointestinal stromal tumors harboring KIT exon 9 mutations: a retrospective, multicenter study","volume":"16","author":"Callejo","year":"2021","journal-title":"Target. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105227_bib8","doi-asserted-by":"crossref","first-page":"iv68","DOI":"10.1093\/annonc\/mdy095","article-title":"Gastrointestinal stromal tumours: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Casali","year":"2018","journal-title":"Ann. Oncol.: Off. J. Eur. Soc. Med. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105227_bib9","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.annonc.2021.09.005","article-title":"Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up","volume":"33","author":"Casali","year":"2022","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"issue":"17","key":"10.1016\/j.critrevonc.2026.105227_bib10","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1158\/1078-0432.CCR-20-0887","article-title":"Model-based dose individualization of sunitinib in gastrointestinal stromal tumors","volume":"26","author":"Centanni","year":"2020","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105227_bib11","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/1477-7819-12-206","article-title":"Laparoscopic versus open resection for gastric gastrointestinal stromal tumors: an updated systematic review and meta-analysis","volume":"12","author":"Chen","year":"2014","journal-title":"World J. Surg. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105227_bib12","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1007\/s00330-018-5629-2","article-title":"Radiomics nomogram for predicting the malignant potential of gastrointestinal stromal tumours preoperatively","volume":"29","author":"Chen","year":"2019","journal-title":"Eur. Radiol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105227_bib13","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1007\/s11605-010-1170-6","article-title":"Management and outcome of gastrointestinal stromal tumors of the duodenum","volume":"14","author":"Chung","year":"2010","journal-title":"J. Gastrointest. Surg.: Off. J. Soc. Surg. Aliment. Trac."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105227_bib14","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1634\/theoncologist.2012-0109","article-title":"Approval summary: Imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors","volume":"17","author":"Cohen","year":"2012","journal-title":"Oncologist"},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105227_bib15","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1200\/JCO.2004.05.140","article-title":"Biology of gastrointestinal stromal tumors","volume":"22","author":"Corless","year":"2004","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105227_bib16","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1470-2045(18)30006-8","article-title":"Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials","volume":"19","author":"D\u2019Angelo","year":"2018","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105227_bib17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00000658-200001000-00008","article-title":"Two hundred gastrointestinal stromal tumors","volume":"231","author":"DeMatteo","year":"2000","journal-title":"Ann. Surg."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105227_bib18","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000156","article-title":"Diagnosis and treatment of duodenal gastrointestinal stromal tumors","volume":"11","author":"Du","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105227_bib19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00000478-199901000-00009","article-title":"Prognosis of gastrointestinal smooth-muscle (stromal) tumors: Dependence on anatomic site","volume":"23","author":"Emory","year":"1999","journal-title":"Am. J. Surg. Pathol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105227_bib20","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1002\/ijc.25827","article-title":"Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review","volume":"128","author":"Essat","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105227_bib21","article-title":"Monitoring circulating tumor DNA during surgical treatment in patients with gastrointestinal stromal tumors","volume":"20","author":"G","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105227_bib22","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1158\/1078-0432.CCR-23-0640","article-title":"A phase I, multicenter, open-label, first-in-human study of DS-6157a in patients with advanced gastrointestinal stromal tumor","volume":"29","author":"George","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105227_bib23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/CCO.0000000000001040","article-title":"Monitoring advanced gastrointestinal stromal tumor with circulating tumor DNA","volume":"36","author":"G\u00f3mez-Peregrina","year":"2024","journal-title":"Curr. Opin. Oncol."},{"issue":"5607","key":"10.1016\/j.critrevonc.2026.105227_bib24","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1126\/science.1079666","article-title":"PDGFRA activating mutations in gastrointestinal stromal tumors","volume":"299","author":"Heinrich","year":"2003","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105227_bib25","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","article-title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial","volume":"21","author":"Heinrich","year":"2020","journal-title":"Lancet Oncol."},{"issue":"5350","key":"10.1016\/j.critrevonc.2026.105227_bib26","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1126\/science.279.5350.577","article-title":"Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors","volume":"279","author":"Hirota","year":"1998","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105227_bib27","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10147-024-02488-1","article-title":"English version of Japanese Clinical Practice Guidelines 2022 for gastrointestinal stromal tumor (GIST) issued by the Japan Society of Clinical Oncology","volume":"29","author":"Hirota","year":"2024","journal-title":"Int. J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105227_bib28","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1002\/bjs.7222","article-title":"Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour","volume":"97","author":"Hohenberger","year":"2010","journal-title":"Br. J. Surg."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105227_bib29","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1158\/2159-8290.CD-20-1434","article-title":"Identification and therapeutic targeting of GPR20, selectively expressed in gastrointestinal stromal tumors, with DS-6157a, a first-in-class antibody-drug conjugate","volume":"11","author":"Iida","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.critrevonc.2026.105227_bib30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21037\/tgh.2018.01.01","article-title":"Neoadjuvant therapy for gastrointestinal stromal tumor","volume":"3","author":"Ishikawa","year":"2018","journal-title":"Transl. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105227_bib31","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1158\/1078-0432.CCR-19-1824","article-title":"Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab","volume":"26","author":"Keung","year":"2020","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105227_bib32","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/1878-0261.13084","article-title":"A novel anti-c-Kit antibody-drug conjugate to treat wild-type and activating-mutant c-Kit-positive tumors","volume":"16","author":"Kim","year":"2022","journal-title":"Mol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105227_bib33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1365-2559.2008.02977.x","article-title":"Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours","volume":"53","author":"Lasota","year":"2008","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105227_bib34","doi-asserted-by":"crossref","DOI":"10.4251\/wjgo.v17.i3.98746","article-title":"Significance of monitoring imatinib plasma concentration in second-line treatment decisions for c-kit 11 gene-mutated gastrointestinal stromal tumors","volume":"17","author":"Li","year":"2025","journal-title":"World J. Gastrointest. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105227_bib35","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00432-016-2334-x","article-title":"Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up","volume":"143","author":"Lin","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105227_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920986498","article-title":"Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward","volume":"13","author":"Lostes-Bardaji","year":"2021","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105227_bib37","doi-asserted-by":"crossref","first-page":"483","DOI":"10.5582\/bst.2017.01183","article-title":"Organ-preserving surgery for locally advanced duodenal gastrointestinal stromal tumor after neoadjuvant treatment","volume":"11","author":"Lv","year":"2017","journal-title":"Biosci. Trends"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105227_bib38","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2229101","article-title":"Exploration of the antibody-drug conjugate clinical landscape","volume":"15","author":"Maecker","year":"2023","journal-title":"mAbs"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105227_bib39","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jamcollsurg.2012.05.008","article-title":"Microscopically positive margins for primary gastrointestinal stromal tumors: analysis of risk factors and tumor recurrence","volume":"215","author":"McCarter","year":"2012","journal-title":"J. Am. Coll. Surg."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105227_bib40","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.6004\/jnccn.2022.0058","article-title":"NCCN Guidelines\u00ae insights: gastrointestinal stromal tumors, version 2.2022: featured updates to the NCCN guidelines","volume":"20","author":"Mehren","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105227_bib41","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00000478-200305000-00006","article-title":"Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases","volume":"27","author":"Miettinen","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105227_bib42","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.semdp.2006.09.001","article-title":"Gastrointestinal stromal tumors: pathology and prognosis at different sites","volume":"23","author":"Miettinen","year":"2006","journal-title":"Semin. Diagn. Pathol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105227_bib43","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.5858\/2006-130-1466-GSTROM","article-title":"Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis, and differential diagnosis","volume":"130","author":"Miettinen","year":"2006","journal-title":"Arch. Pathol. Lab. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105227_bib44","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.pas.0000146010.92933.de","article-title":"Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up","volume":"29","author":"Miettinen","year":"2005","journal-title":"Am. J. Surg. Pathol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105227_bib45","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000521751","article-title":"KIT Exon 9-mutated gastrointestinal stromal tumours: biology and treatment","volume":"67","author":"Napolitano","year":"2022","journal-title":"Chemotherapy"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105227_bib46","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1007\/s10120-022-01310-z","article-title":"Long-term adjuvant therapy for high-risk gastrointestinal stromal tumors in the real world","volume":"25","author":"Nishida","year":"2022","journal-title":"Gastr. Cancer: Off. J. Int. Gastr. Cancer Assoc. Jpn. Gastr. Cancer Assoc."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105227_bib47","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20150089","article-title":"Antibody-drug conjugates as novel anti-cancer chemotherapeutics","volume":"35","author":"Peters","year":"2015","journal-title":"Biosci. Rep."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105227_bib48","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/14728214.2021.1896704","article-title":"Emerging drugs for the treatment of gastrointestinal stromal tumors","volume":"26","author":"Pilco-Janeta","year":"2021","journal-title":"Expert Opin. Emerg. Drugs"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105227_bib49","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.4060","article-title":"Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor","volume":"4","author":"Raut","year":"2018","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105227_bib50","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1245\/s10434-013-3013-7","article-title":"Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience","volume":"20","author":"Rutkowski","year":"2013","journal-title":"Ann. Surg. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105227_bib51","article-title":"Circulating cKIT and PDGFRA DNA indicates disease activity in gastrointestinal stromal tumor (GIST)","volume":"145","author":"S","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105227_bib52","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.acra.2021.05.005","article-title":"Radiomics nomogram based on contrast-enhanced CT to predict the malignant potential of gastrointestinal stromal tumor: a two-center study","volume":"29","author":"Song","year":"2022","journal-title":"Acad. Radiol."},{"key":"10.1016\/j.critrevonc.2026.105227_bib53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canep.2015.10.031","article-title":"Global epidemiology of gastrointestinal stromal tumours (GIST): a systematic review of population-based cohort studies","volume":"40","author":"S\u00f8reide","year":"2016","journal-title":"Cancer Epidemiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105227_bib54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","article-title":"Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: a phase 2 clinical trial","volume":"4","author":"Toulmonde","year":"2018","journal-title":"JAMA Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105227_bib55","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1572-0241.2005.40709.x","article-title":"The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1458 cases from 1992 to 2000","volume":"100","author":"Tran","year":"2005","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2026.105227_bib56","article-title":"DOG1 as a novel antibody-drug conjugate target for the treatment of multiple gastrointestinal tumors and liver metastasis","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105227_bib57","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40169-020-0263-4","article-title":"Personalized CT-based radiomics nomogram preoperative predicting Ki-67 expression in gastrointestinal stromal tumors: a multicenter development and validation cohort","volume":"9","author":"Zhang","year":"2020","journal-title":"Clin. Transl. Med."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105227_bib58","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s12967-023-04063-0","article-title":"Mesenchymal stromal cells promote the drug resistance of gastrointestinal stromal tumors by activating the PI3K-AKT pathway via TGF-\u03b22","volume":"21","author":"Zhao","year":"2023","journal-title":"J. Transl. Med."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T03:21:51Z","timestamp":1777605711000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":58,"alternative-id":["S1040842826001149"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105227","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Navigating the complex landscape of duodenal gastrointestinal stromal tumor: Innovations in diagnosis and treatment","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105227","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105227"}}